Data on the treatment and management of HFmrEF are limited, but a new scientific statement from the Heart Failure Society of America highlights how important it is to take this condition seriously.

Short-term outcomes were comparable, but long-term data revealed a significant difference in all-cause mortality.

Researchers explored data from more than 8,000 patients treated over a three-year period. 

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial. 

The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.

AI can help care teams get additional value out of routine head CT images.